Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD40.Pan.CoV vaccine adjuvanted with Hiltonol
- Development stage
- Phase 2
- Lead developer
- EnnoDC
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
CD40.Pan.CoV vaccine adjuvanted with Hiltonol is an experimental pan-coronavirus vaccine candidate developed by ANRS, Emerging Infectious Diseases and the Vaccine Research Institute (VRI). The vaccine component, CD40.Pan.CoV, is a protein subunit vaccine consisting of a monoclonal antibody fragment targeting the CD40 receptor on antigen-presenting cells (APCs) fused to conserved coronavirus antigens. This targeting mechanism is designed to enhance the activation of dendritic cells and subsequent T-cell and B-cell immune responses. The vaccine is formulated with Hiltonol (Poly-ICLC), a synthetic double-stranded RNA that acts as a Toll-like receptor 3 (TLR3) and MDA5 agonist, providing a potent adjuvant effect to stimulate innate immunity. It is currently being investigated in the Phase 1 SOLVE-01 clinical trial as a booster dose in healthy adults previously vaccinated with authorized mRNA COVID-19 vaccines.
- Other names
- CD40.Pan.CoV vaccineCD-40.Pan.CoV vaccineCD 40.Pan.CoV vaccineCD40.Pan.CoV + Hiltonol
02
Targets
CD40 (Cluster of differentiation 40 receptor)IFIH1 (MDA5)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on CD40.Pan.CoV vaccine adjuvanted with Hiltonol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD40.Pan.CoV vaccine adjuvanted with Hiltonol.